Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Total Current Assets

All assets expected to be converted to cash or used up within one year.

No reported Total Current Assets figures are available to summarize.

Total Current Assets history

Currency unavailable · from the balance sheet

No Total Current Assets data reported for this period type.

Total Current Assets vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Total Current Assets for KARD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CYTKCytokinetics, IncorporatedJun 2026$1.21B USD+36.3%+4.9%62.8%
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$659.21M USD-14.4%+12.2%93.6%
RNAAtrium Therapeutics, Inc.Mar 2026$285.57M USD——97.7%
IKTInhibikase Therapeutics, Inc.Mar 2026$172.18M USD+82.8%+94.8%99.3%
TNYATenaya Therapeutics, Inc.Mar 2026$96.56M USD+2.2%-18.3%71.5%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+19.3%+8.5%93.6%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.